These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Enhanced in vivo antifungal activity of novel cell penetrating peptide natamycin conjugate for efficient fungal keratitis management. Rohira H; Shankar S; Yadav S; Shah SG; Chugh A Int J Pharm; 2021 May; 600():120484. PubMed ID: 33737097 [TBL] [Abstract][Full Text] [Related]
44. Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs. Yin X; Daintree LS; Ding S; Ledger DM; Wang B; Zhao W; Qi J; Wu W; Han J Drug Des Devel Ther; 2015; 9():2801-10. PubMed ID: 26060397 [TBL] [Abstract][Full Text] [Related]
45. Medical interventions for fungal keratitis. FlorCruz NV; Peczon IV; Evans JR Cochrane Database Syst Rev; 2012 Feb; (2):CD004241. PubMed ID: 22336802 [TBL] [Abstract][Full Text] [Related]
46. Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles. Qiu L; Hu B; Chen H; Li S; Hu Y; Zheng Y; Wu X Int J Nanomedicine; 2015; 10():1415-23. PubMed ID: 25733833 [TBL] [Abstract][Full Text] [Related]
47. Optimization and Characterization of Aqueous Micellar Formulations for Ocular Delivery of an Antifungal Drug, Posaconazole. Durgun ME; Kahraman E; Güngör S; Özsoy Y Curr Pharm Des; 2020; 26(14):1543-1555. PubMed ID: 32167423 [TBL] [Abstract][Full Text] [Related]
48. A Novel Nanoemulsion Intermediate Gel as a Promising Approach for Delivery of Itraconazole: Design, In Vitro and Ex Vivo Appraisal. Botros SR; Hussein AK; Mansour HF AAPS PharmSciTech; 2020 Oct; 21(7):272. PubMed ID: 33025308 [TBL] [Abstract][Full Text] [Related]
49. Itraconazole-hydroxypropyl-β-cyclodextrin loaded deformable liposomes: in vitro skin penetration studies and antifungal efficacy using Candida albicans as model. Alomrani AH; Shazly GA; Amara AA; Badran MM Colloids Surf B Biointerfaces; 2014 Sep; 121():74-81. PubMed ID: 24937135 [TBL] [Abstract][Full Text] [Related]
50. In vitro efficacy of a buffered chelating solution as an antimicrobial potentiator for antifungal drugs against fungal pathogens obtained from horses with mycotic keratitis. Weinstein WL; Moore PA; Sanchez S; Dietrich UM; Wooley RE; Ritchie BW Am J Vet Res; 2006 Apr; 67(4):562-8. PubMed ID: 16579746 [TBL] [Abstract][Full Text] [Related]
51. Condition responsive nanoparticles for managing infection and inflammation in keratitis. Ahsan SM; Rao CM Nanoscale; 2017 Jul; 9(28):9946-9959. PubMed ID: 28681884 [TBL] [Abstract][Full Text] [Related]
53. Improved antifungal activity of itraconazole-loaded PEG/PLA nanoparticles. Essa S; Louhichi F; Raymond M; Hildgen P J Microencapsul; 2013; 30(3):205-17. PubMed ID: 22894166 [TBL] [Abstract][Full Text] [Related]
54. Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods. Iqbal NJ; Boey A; Park BJ; Brandt ME Diagn Microbiol Infect Dis; 2008 Nov; 62(3):348-50. PubMed ID: 18707841 [TBL] [Abstract][Full Text] [Related]
55. A vaginal drug delivery model. Mirza MA; Panda AK; Asif S; Verma D; Talegaonkar S; Manzoor N; Khan A; Ahmed FJ; Dudeja M; Iqbal Z Drug Deliv; 2016 Oct; 23(8):3123-3134. PubMed ID: 26971617 [TBL] [Abstract][Full Text] [Related]
56. Clinical characteristics of keratitis due to Colletotrichum gloeosporioides. Shiraishi A; Araki-Sasaki K; Mitani A; Miyamoto H; Sunada A; Ueda A; Asari S; Zheng X; Yamamoto Y; Hara Y; Ohashi Y J Ocul Pharmacol Ther; 2011 Oct; 27(5):487-91. PubMed ID: 21770739 [TBL] [Abstract][Full Text] [Related]
57. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses. Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621 [TBL] [Abstract][Full Text] [Related]
59. In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery. Al Khateb K; Ozhmukhametova EK; Mussin MN; Seilkhanov SK; Rakhypbekov TK; Lau WM; Khutoryanskiy VV Int J Pharm; 2016 Apr; 502(1-2):70-9. PubMed ID: 26899977 [TBL] [Abstract][Full Text] [Related]